Submitted:
25 May 2025
Posted:
29 May 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Methods
2.1. Study Design and Setting
2.2. Study Participants
2.2.1. Inclusion Criteria:
2.2.2. Exclusion Criteria:
2.2.3. After applying the inclusion and exclusion criteria, a total of 960 patients were enrolled in the study.
2.3. Data Collection
- ◦
- Anthropometric Measurements: Height, weight, BMI, and Waist Circumference.
- ◦
- Clinical and Laboratory Data: Blood pressure (systolic and diastolic) and glycated hemoglobin (HbA1c) levels.
- ◦
- Obesity-related comorbidities recorded by the physician at the time of first patient visit, namely hypertension, fatty liver, prediabetes, diabetes, hypothyroidism, and obstructive sleep apnea.
- ◦
- Obesity management, including liraglutide (Saxenda) prescription, referral to a dietitian, health education, psychiatrist, psychologist, endocrinologist, pulmonologist, and clinical pharmacists.
- ◦
- Based on clinical records at the time of the patient’s first visit, the EOSS stage and the stage of change were recorded as well.
2.4. Working Definitions
2.5. Statistical Analysis
2.5.1. Ethical Consideration
2.5.2. Budget
3. Results
4. Discussion
6. Conclusion
Author Contributions
Data Availability Statement
Conflicts of Interest
Appendix A
- Normal HbA1c levels without a diagnosis of diabetes
- Normal blood pressure without a diagnosis of hypertension
- No diagnosis of dyslipidemia
- Negative depression screening test
- Negative obstructive sleep apnea screening based on the STOP-BANG questionnaire (S: Snoring, T: Tiredness, O: Observed apnea, P: high blood pressure, B: Body mass index, A: Age, N: Neck circumference, and G: Gender)
- Patients are classified into Stage 1 if they exhibit any of the following:
- Prediabetes diagnosis or elevated HbA1c levels
- Pre-hypertension diagnosis or elevated blood pressure levels
- Dyslipidemia diagnosis
- Positive depression screening test, but without requiring referral to a psychiatrist/psychologist
- Negative obstructive sleep apnea screening based on the STOP-BANG questionnaire
- Patients are classified into Stage 2 if they meet any of the following conditions:
- Diabetes diagnosis or HbA1c levels indicative of diabetes
- Hypertension diagnosis or elevated blood pressure levels
- Positive depression screening test requiring referral to a psychiatrist/psychologist
- Positive obstructive sleep apnea screening by STOP-BANG questionnaire, requiring referral for a sleep study
References
- J., A. Q., M. S., P., J. A., C., E., S., & M., O. (2014). Trends and future projections of the prevalence of adult obesity in Saudi Arabia, 1992-2022. 589–595. https://pesquisa.bvsalud.org/portal/resource/pt/emr-159248.
- Ali, S., Khan, O. S., Youssef, A. M., Saba, I., Alqahtani, L., Alduhaim, R. A., & Almesned, R. (2024). Predicting COVID-19 outcomes with the Edmonton Obesity Staging System. Annals of Saudi Medicine, 44(2), 116–125. [CrossRef]
- Al-Rubeaan, K., Bawazeer, N., Al Farsi, Y., Youssef, A. M., Al-Yahya, A. A., AlQumaidi, H., Al-Malki, B. M., Naji, K. A., Al-Shehri, K., & Al Rumaih, F. I. (2018). Prevalence of metabolic syndrome in Saudi Arabia—A cross sectional study. BMC Endocrine Disorders, 18(1), 16. [CrossRef]
- Atlantis, E., Sahebolamri, M., Cheema, B. S., & Williams, K. (2020). Usefulness of the Edmonton Obesity Staging System for stratifying the presence and severity of weight-related health problems in clinical and community settings: A rapid review of observational studies. Obesity Reviews, 21(11), e13120. [CrossRef]
- Canning, K. L., Brown, R. E., Wharton, S., Sharma, A. M., & Kuk, J. L. (2015). Edmonton Obesity Staging System Prevalence and Association with Weight Loss in a Publicly Funded Referral-Based Obesity Clinic. Journal of Obesity, 2015(1), 619734. [CrossRef]
- Chiappetta, S., Stier, C., Squillante, S., Theodoridou, S., & Weiner, R. A. (2016). The importance of the Edmonton Obesity Staging System in predicting postoperative outcome and 30-day mortality after metabolic surgery. Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery, 12(10), 1847–1855. [CrossRef]
- De Wolf, A., Nauwynck, E., Vanbesien, J., Staels, W., De Schepper, J., & Gies, I. (2024). Optimizing Childhood Obesity Management: The Role of Edmonton Obesity Staging System in Personalized Care Pathways. Life, 14(3), Article 3. [CrossRef]
- Dobbie, L. J., Coelho, C., Crane, J., & McGowan, B. (2023). Clinical evaluation of patients living with obesity. Internal and Emergency Medicine, 18(5), 1273–1285. [CrossRef]
- Huxley, R., Mendis, S., Zheleznyakov, E., Reddy, S., & Chan, J. (2010). Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk—A review of the literature. European Journal of Clinical Nutrition, 64(1), 16–22. [CrossRef]
- Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., & Kushner, R. F. (2014). Reprint: 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Pharm Assoc, 54(1), e3. https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=7c28596b33491c05d557becba3861acc0562df51.
- Kissebah, A. H., & Krakower, G. R. (1994). Regional adiposity and morbidity. Physiological Reviews, 74(4), 761–811. [CrossRef]
- Konswa, A. A., Alolaiwi, L., Alsakkak, M., Aleissa, M., Alotaibi, A., Alanazi, F. F., & Rasheed, A. bin. (2023). Experience of establishing a lifestyle medicine clinic at primary care level- challenges and lessons learnt. Journal of Taibah University Medical Sciences, 18(6), 1364–1372. [CrossRef]
- Kuk, J. L., Ardern, C. I., Church, T. S., Sharma, A. M., Padwal, R., Sui, X., & Blair, S. N. (2011). Edmonton Obesity Staging System: Association with weight history and mortality risk. Applied Physiology, Nutrition, and Metabolism, 36(4), 570–576. [CrossRef]
- Lehnert, T., Sonntag, D., Konnopka, A., Riedel-Heller, S., & König, H.-H. (2013). Economic costs of overweight and obesity. Best Practice & Research Clinical Endocrinology & Metabolism, 27(2), 105–115. [CrossRef]
- Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., Abegaz, K. H., Abolhassani, H., Aboyans, V., Abreu, L. G., Abrigo, M. R. M., Abualhasan, A., Abu-Raddad, L. J., Abushouk, A. I., Adabi, M., … Lim, S. S. (2020). Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10258), 1223–1249. [CrossRef]
- Myung, J., Jung, K. Y., Kim, T. H., & Han, E. (2019). Assessment of the validity of multiple obesity indices compared with obesity-related co-morbidities. Public Health Nutrition, 22(7), 1241–1249. [CrossRef]
- Ortega, F. B., Lavie, C. J., & Blair, S. N. (2016). Obesity and Cardiovascular Disease. Circulation Research, 118(11), 1752–1770. [CrossRef]
- Padwal, R. S., Pajewski, N. M., Allison, D. B., & Sharma, A. M. (2011). Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ, 183(14), E1059–E1066. [CrossRef]
- Puhl, R. M., & Heuer, C. A. (2009). The Stigma of Obesity: A Review and Update. Obesity, 17(5), 941–964. [CrossRef]
- Rodríguez-Flores, M., Goicochea-Turcott, E. W., Mancillas-Adame, L., Garibay-Nieto, N., López-Cervantes, M., Rojas-Russell, M. E., Castro-Porras, L. V., Gutiérrez-León, E., Campos-Calderón, L. F., Pedraza-Escudero, K., Aguilar-Cuarto, K., Villanueva-Ortega, E., Hernández-Ruíz, J., Guerrero-Avendaño, G., Monzalvo-Reyes, S. M., García-Rascón, R., Gil-Velázquez, I. N., Cortés-Hernández, D. E., Granados-Shiroma, M., … Gregg, E. W. (2022). The utility of the Edmonton Obesity Staging System for the prediction of COVID-19 outcomes: A multi-centre study. International Journal of Obesity (2005), 46(3), 661–668. [CrossRef]
- Sharma, A. M., & Kushner, R. F. (2009). A proposed clinical staging system for obesity. International Journal of Obesity, 33(3), 289–295. [CrossRef]
- Swaleh, R., McGuckin, T., Myroniuk, T. W., Manca, D., Lee, K., Sharma, A. M., Campbell-Scherer, D., & Yeung, R. O. (2021). Using the Edmonton Obesity Staging System in the real world: A feasibility study based on cross-sectional data. Canadian Medical Association Open Access Journal, 9(4), E1141–E1148. [CrossRef]
- Wildman, R. P., Muntner, P., Reynolds, K., McGinn, A. P., Rajpathak, S., Wylie-Rosett, J., & Sowers, M. R. (2008). The Obese Without Cardiometabolic Risk Factor Clustering and the Normal Weight With Cardiometabolic Risk Factor Clustering: Prevalence and Correlates of 2 Phenotypes Among the US Population (NHANES 1999-2004). Archives of Internal Medicine, 168(15), 1617–1624. [CrossRef]


| Characteristic | Mean ± SD | n | Percentage (%) |
| Age (years) | 39.17 ± 10.36 | - | - |
| Sex | |||
| Male | - | 282 | 29.4% |
| Female | - | 678 | 70.6% |
| Currently Smokers | - | 55 | 5.7% |
| On Low-Caloric Diet | - | 151 | 15.7% |
| Physical Activity (≥150 min/week) | - | 132 | 13.8% |
| Height (cm) | 161 ± 9 | - | - |
| Weight (Kg) | 93 ± 14 | - | - |
| Body Mass Index (Kg/m²) | 36 ± 4 | - | - |
| Waist Circumference (cm) | 106 ± 11 | - | - |
| Male Waist Circumference (cm) | 114 ± 10 | - | - |
| Female Waist Circumference (cm) | 104 ± 10 | - | - |
| Systolic Blood Pressure (mm Hg) | 124 ± 14 | - | - |
| Diastolic Blood Pressure (mm Hg) | 77 ± 9 | - | - |
| HbA1c (%) | 5.70 ± 0.43 | - | - |
| Comorbidities | N | Percentage (%) |
| Prediabetes | 678 | 70.6% |
| Dyslipidemia | 593 | 61.8% |
| Hypertension | 184 | 19.2% |
| Hypothyroidism | 116 | 12.1% |
| Depression | 54 | 5.6% |
| Diabetes | 12 | 1.3% |
| Moderate to high risk for obstructive sleep apnea by STOP-BANG screening tool | 11 | 1.1% |
| Fatty liver disease | 6 | 0.6% |
| Characteristic |
EOSS stage 0 N (%) Mean ± SD |
EOSS stage 1 N (%) Mean ± SD |
EOSS stage 2 N (%) Mean ± SD |
P value ± 95%CI |
| Age (40 and above) | 81 (35.7%) | 283 (50.2%) | 101 (59.8%) | <0.001 |
|
Sex Male |
||||
| 42 (18.5%) | 164 (29.1%) | 76 (45.0%) | <0.001 | |
| Female | 185 (81.5%) | 400 (70.9%) | 93 (55.0%) | |
| Currently Smokers | 9 (4.0%) | 34 (6.0%) | 12 (7.1%) | 0.370 |
| On Low-Caloric Diet | 35 (15.4%) | 93 (16.5%) | 23 (13.6%) | 0.659 |
| Physical Activity (≥150 min/week) | 29 (12.8%) | 81 (14.4%) | 22 (13.0%) | 0.804 |
| Height (cm) | 160 ± 7 | 161 ± 9 | 163 ± 10 | <0.001 |
| Weight (Kg) | 90 ± 13 | 93 ±14 | 96± 14 | <0.001 |
| Body Mass Index (Kg/m²) | 35 ± 4 | 36 ± 4 | 36 ± 4 | 0.007 |
| Waist Circumference (cm) | 103 ± 11 | 106 ± 11 | 108 ± 9 | <0.001 |
| Systolic Blood Pressure (mm Hg) | 120 ± 11 | 121 ± 12 | 136 ± 14 | <0.001 |
| Diastolic Blood Pressure (mm Hg) | 76 ± 7 | 75 ± 7 | 86 ± 10 | <0.001 |
| HbA1c (%) | 5.1 ±0.2 | 5.9 ± 0.2 | 5.8 ± 0.5 | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).